Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) Presents at 46th Annual William Blair Growth Stock Conference Transcript
CRISPR Therapeutics AG (CRSP) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
These Are The Upcoming Catalysts For Crispr Therapeutics Stock
Crispr Therapeutics AG remains a Buy, supported by a robust pipeline, prudent capital management, and deep Vertex partnership despite slow Casgevy adoption. Casgevy's market penetration is limited by harsh preconditioning, but in vivo approaches and gentler regimens could unlock a vastly larger TAM in coming years. CRSP's diversified pipeline—spanning cardiovascular, diabetes, and CAR-T—offers multiple shots on goal, with key clinical readouts expected throughout 2026.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms
CRISPR Therapeutics NASDAQ: CRSP Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months.
CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript
CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates
CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $1.58 per share a year ago.
Why the Market Dipped But CRISPR Therapeutics AG (CRSP) Gained Today
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $52.06, representing a +2.1% change from its previous close.
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
